GlassScriptPhysician profile
Hope Dukes
NPI 1134720261
$5,960.80
in general payments reported to CMS, 2019-2025
29 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $623 · 2022: $2,081 · 2023: $1,172 · 2024: $1,024 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,256.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $909.82 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $709.82 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $570.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $540.31 | 2021-2025 | |
| Pfizer INC. | $404.95 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $399.64 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $334.80 | 2022-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.17 | 2021-2024 | Jardiance |
| Dexcom, INC. | $248.52 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $240.53 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $169.53 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $147.38 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $134.17 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $124.44 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $122.63 | 2022-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $109.94 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $69.38 | 2024 | Voquezna |
| Axsome Therapeutics, INC. | $63.30 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $54.71 | 2021-2022 | |
| Astellas Pharma US INC | $44.29 | 2021-2023 | Veozah, Myrbetriq |
| Tris Pharma INC | $37.10 | 2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $34.44 | 2023-2024 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $31.78 | 2021 | |
| Exact Sciences Corporation | $24.18 | 2023 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $22.52 | 2021 | |
| Dynavax Technologies Corporation | $19.69 | 2025 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $17.19 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $15.73 | 2025 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hope Dukes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.